Proteo Inc. (fka PTEO)

[vinnybotz]

email from IR:


"The FDA grants orphan drug designation to Elafin for prevention of inflammatory complications of transthoracic esophagectomy.

The orphan drug designation was established to encourage development of drugs that support the diagnosis, prevention or treatment of a medical condition affecting fewer than 200,000 people in the U.S. The designation provides U.S. market exclusivity for a seven-year period upon marketing approval for the designated indication and tax credits for clinical research costs.

Granting orphan drug designation does not mean that the FDA has given marketing approval for this indication."



Best regards,

Proteo IR Team



Proteo, Inc.

2102 Business Center Drive, Suite 130

Irvine CA 92612

USA

[e-mail]

Phone [phone]